You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Dow
McKinsey
Baxter
Colorcon
McKesson
Boehringer Ingelheim

Last Updated: July 12, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for MLN1202


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the drug development status for MLN1202?

MLN1202 is an investigational drug.

There have been 7 clinical trials for MLN1202. The most recent clinical trial was a Phase 2 trial, which was initiated on April 1st 2016.

The most common disease conditions in clinical trials are Cardiovascular Diseases, Atherosclerosis, and Multiple Sclerosis. The leading clinical trial sponsors are Takeda, Millennium Pharmaceuticals, Inc., and Southwest Oncology Group.

There are three US patents protecting this investigational drug and thirty-one international patents.

Recent Clinical Trials for MLN1202
TitleSponsorPhase
Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced MelanomaMillennium Pharmaceuticals, Inc.Phase 1
Proof of Mechanism Study of MLN1202 on Atherosclerotic Inflammation in Participants With Stable Atherosclerotic Cardiovascular DiseaseTakedaPhase 2
Efficacy and Safety of Weekly Subcutaneous MLN1202 in Improving Diabetic Nephropathy in Participants With MacroalbuminuriaTakedaPhase 2

See all MLN1202 clinical trials

Clinical Trial Summary for MLN1202

Top disease conditions for MLN1202
Top clinical trial sponsors for MLN1202

See all MLN1202 clinical trials

US Patents for MLN1202

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
MLN1202   Start Trial Methods for glycoprotein remodeling using endoglycosidase mutants CHO Pharma Inc. (Taipei, TW) Academia Sinica (Taipei, TW)   Start Trial
MLN1202   Start Trial Pretreatment of a biological sample from an autoimmune disease subject Genentech, Inc. (South San Francisco, CA)   Start Trial
MLN1202   Start Trial Chemoenzymatic glycoengineering of antibodies and Fc fragments thereof UNIVERSITY OF MARYLAND, BALTIMORE (Baltimore, MD)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for MLN1202

Drugname Country Document Number Estimated Expiration Related US Patent
MLN1202 Australia 2017315677 2036-08-24   Start Trial
MLN1202 Canada 3034876 2036-08-24   Start Trial
MLN1202 China 110234341 2036-08-24   Start Trial
MLN1202 European Patent Office 3532090 2036-08-24   Start Trial
MLN1202 Japan 2020500549 2036-08-24   Start Trial
MLN1202 South Korea 20190039580 2036-08-24   Start Trial
MLN1202 Taiwan 201823455 2036-08-24   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKinsey
Boehringer Ingelheim
Harvard Business School
Express Scripts
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.